1134 related articles for article (PubMed ID: 30962192)
1. Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction.
Salah K; Stienen S; Pinto YM; Eurlings LW; Metra M; Bayes-Genis A; Verdiani V; Tijssen JGP; Kok WE
Heart; 2019 Aug; 105(15):1182-1189. PubMed ID: 30962192
[TBL] [Abstract][Full Text] [Related]
2. Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction.
Savarese G; Orsini N; Hage C; Dahlström U; Vedin O; Rosano GMC; Lund LH
J Card Fail; 2018 Jun; 24(6):365-374. PubMed ID: 29597053
[TBL] [Abstract][Full Text] [Related]
3. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction.
Santhanakrishnan R; Chong JP; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong R; Chai P; Low AF; Richards AM; Lam CS
Eur J Heart Fail; 2012 Dec; 14(12):1338-47. PubMed ID: 22869458
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers for characterization of heart failure - Distinction of heart failure with preserved and reduced ejection fraction.
Sinning C; Kempf T; Schwarzl M; Lanfermann S; Ojeda F; Schnabel RB; Zengin E; Wild PS; Lackner KJ; Munzel T; Blankenberg S; Wollert KC; Zeller T; Westermann D
Int J Cardiol; 2017 Jan; 227():272-277. PubMed ID: 27838133
[TBL] [Abstract][Full Text] [Related]
5. Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes.
Zabarovskaja S; Hage C; Linde C; Daubert JC; Donal E; Gabrielsen A; Mellbin L; Lund LH
Int J Cardiol; 2015; 189():6-11. PubMed ID: 25885866
[TBL] [Abstract][Full Text] [Related]
6. Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction.
Savarese G; Hage C; Orsini N; Dahlström U; Perrone-Filardi P; Rosano GM; Lund LH
Circ Heart Fail; 2016 Nov; 9(11):. PubMed ID: 28029640
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF.
Kang SH; Park JJ; Choi DJ; Yoon CH; Oh IY; Kang SM; Yoo BS; Jeon ES; Kim JJ; Cho MC; Chae SC; Ryu KH; Oh BH;
Heart; 2015 Dec; 101(23):1881-8. PubMed ID: 26319121
[TBL] [Abstract][Full Text] [Related]
8. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).
Maeder MT; Rickenbacher P; Rickli H; Abbühl H; Gutmann M; Erne P; Vuilliomenet A; Peter M; Pfisterer M; Brunner-La Rocca HP;
Eur J Heart Fail; 2013 Oct; 15(10):1148-56. PubMed ID: 23657728
[TBL] [Abstract][Full Text] [Related]
9. N-terminal pro-B-type natriuretic peptide in chronic heart failure: The impact of sex across the ejection fraction spectrum.
Faxén UL; Lund LH; Orsini N; Strömberg A; Andersson DC; Linde C; Dahlström U; Savarese G
Int J Cardiol; 2019 Jul; 287():66-72. PubMed ID: 31005415
[TBL] [Abstract][Full Text] [Related]
10. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction.
Chan MM; Santhanakrishnan R; Chong JP; Chen Z; Tai BC; Liew OW; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong RC; Chai P; Low AF; Richards AM; Lam CS
Eur J Heart Fail; 2016 Jan; 18(1):81-8. PubMed ID: 26497848
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of sST2 and NT-proBNP at admission in heart failure with preserved, mid-ranged and reduced ejection fraction.
Huang A; Qi X; Hou W; Qi Y; Zhao N; Liu K
Acta Cardiol; 2018 Feb; 73(1):41-48. PubMed ID: 28944719
[TBL] [Abstract][Full Text] [Related]
12. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study.
Ezekowitz JA; O'Connor CM; Troughton RW; Alemayehu WG; Westerhout CM; Voors AA; Butler J; Lam CSP; Ponikowski P; Emdin M; Patel MJ; Pieske B; Roessig L; Hernandez AF; Armstrong PW
JACC Heart Fail; 2020 Nov; 8(11):931-939. PubMed ID: 33039447
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and prognosis of heart failure with preserved ejection fraction and elevated N-terminal pro brain natriuretic peptide: a 10-year analysis from the Copenhagen Hospital Heart Failure Study.
Carlsen CM; Bay M; Kirk V; Gøtze JP; Køber L; Nielsen OW
Eur J Heart Fail; 2012 Mar; 14(3):240-7. PubMed ID: 22315457
[TBL] [Abstract][Full Text] [Related]
15. Limited value of NT-proBNP as a prognostic marker of all-cause mortality in patients with heart failure with preserved and mid-range ejection fraction in primary care: A report from the swedish heart failure register.
Eriksson B; Wändell P; Dahlström U; Näsman P; Lund LH; Edner M
Scand J Prim Health Care; 2019 Dec; 37(4):434-443. PubMed ID: 31724475
[No Abstract] [Full Text] [Related]
16. Highest Obesity Category Associated With Largest Decrease in N-Terminal Pro-B-Type Natriuretic Peptide in Patients Hospitalized With Heart Failure With Preserved Ejection Fraction.
Vaishnav J; Chasler JE; Lee YJ; Ndumele CE; Hu JR; Schulman SP; Russell SD; Sharma K
J Am Heart Assoc; 2020 Aug; 9(15):e015738. PubMed ID: 32750299
[TBL] [Abstract][Full Text] [Related]
17. Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study.
Lam CSP; Gamble GD; Ling LH; Sim D; Leong KTG; Yeo PSD; Ong HY; Jaufeerally F; Ng TP; Cameron VA; Poppe K; Lund M; Devlin G; Troughton R; Richards AM; Doughty RN
Eur Heart J; 2018 May; 39(20):1770-1780. PubMed ID: 29390051
[TBL] [Abstract][Full Text] [Related]
18. Utilizing NT-proBNP for Eligibility and Enrichment in Trials in HFpEF, HFmrEF, and HFrEF.
Savarese G; Orsini N; Hage C; Vedin O; Cosentino F; Rosano GMC; Dahlström U; Lund LH
JACC Heart Fail; 2018 Mar; 6(3):246-256. PubMed ID: 29428439
[TBL] [Abstract][Full Text] [Related]
19. Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction.
Tromp J; Khan MA; Klip IT; Meyer S; de Boer RA; Jaarsma T; Hillege H; van Veldhuisen DJ; van der Meer P; Voors AA
J Am Heart Assoc; 2017 Mar; 6(4):. PubMed ID: 28360225
[TBL] [Abstract][Full Text] [Related]
20. N-terminal pro-B-type natriuretic peptide post-discharge monitoring in the management of patients with heart failure and preserved ejection fraction - a randomized trial: The NICE study.
Pascual-Figal DA; Hernández-Vicente A; Pastor-Pérez F; Martínez-Sellés M; Solé-González E; Alvarez-García J; García-Pavía P; Varela-Román A; Sánchez PL; Delgado JF; Noguera-Velasco JA; Bayes-Genis A;
Eur J Heart Fail; 2024 Apr; 26(4):776-784. PubMed ID: 38606524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
